Stratification of patients can be conducted on the basis of age at the diagnosis, International Neuroblastoma Staging System (INSS) stage, the MYCN status, Shimada histopathology, and ploidy, defining three well discriminated groups of low, intermediated, and high risk77. This evidence concerns the gene MYCN and neuroblastoma.